Irinotecan
HR-positive, HER2-negative Advanced Breast Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Small moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the HR-positive, HER2-negative Advanced Breast Cancer cohort.
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →